1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC)
    Meeting Abstract

    Wu, J. J.; Atkinson, E. C.; Leichman, L. P.; Patel, H.; Iqbal, S.; Du, K. L.; Bizekis, C.; Goldberg, J. D.; Thomas, C. R.; Cohen, D. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pancreatic ductal adenocarcinoma (PDAC), BRCA: Detailed analysis and outcomes of cohort from Memorial Sloan Kettering Cancer Center (MSK)
    Meeting Abstract

    Momtaz, P.; O'Connor, C. A.; Chou, J. F.; Capanu, M.; Yu, K. H.; Varghese, A. M.; Park, W.; Zervoudakis, A.; Li, J.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma
    Meeting Abstract

    Ly, M.; Molena, D.; Sihag, S.; Wu, A. J. C.; Shah, P. M.; Gu, P.; Sugarman, R.; Maron, S. B.; Chalasani, S. B.; Shcherba, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase 1 dose escalation study of PRS-343, a HER2/4-1bb bispecific molecule, in patients with HER2-positive malignancies
    Meeting Abstract

    Piha-Paul, S.; Bendell, J.; Tolcher, A.; Hurvitz, S.; Patnaik, A.; Shroff, R.; Pohlmann, P.; Zettl, M.; Hahn, N.; Krishnamurthy, A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Establishing cGMP manufacturing of CRISPR/Cas9-edited human CAR T cells
    Meeting Abstract

    Wang, X.; Zabierowski, S.; Wu, M.; Del Casale, C.; Eyquem, J.; Mansilla-Soto, J.; Riviere, I.; Sadelain, M.
    Cytotherapy (2020)

    Fulltext@MSK | Save
  • T cell-based immunotherapy for a "public" neoantigen derived from a PIK3CA hotspot mutation
    Meeting Abstract

    Klebanoff, C.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade
    Journal Article

    Warner, A. B.; Palmer, J. S.; Shoushtari, A. N.; Goldman, D. A.; Panageas, K. S.; Hayes, S. A.; Bajwa, R.; Momtaz, P.; Callahan, M. K.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer
    Journal Article

    Mayadev, J.; Zamarin, D.; Deng, W.; Lankes, H.; O'Cearbhaill, R.; Aghajanian, C. A.; Schilder, R.
    International Journal of Gynecological Cancer (2020)

    Fulltext@MSK | Save
  • Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer
    Journal Article

    Schoenfeld, A. J.; Chan, J. M.; Kubota, D.; Sato, H.; Rizvi, H.; Daneshbod, Y.; Chang, J. C.; Paik, P. K.; Offin, M.; Arcila, M. E.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): A multicenter, open-label phase 2 trial
    Journal Article

    Jagasia, M.; Perales, M. A.; Schroeder, M. A.; Ali, H.; Shah, N. N.; Chen, Y. B.; Fazal, S.; Dawkins, F. W.; Arbushites, M. C.; Tian, C.; more...
    Blood (2020)

    Fulltext@MSK | Save